Hepatitis is an inflammation of the liver mainly induced by autoimmunity, chemical, or infectious agents. In the United States, the third most prevalent form of chronic infectious hepatitis is caused by hepatitis C virus (HCV). Worldwide there are an estimated 170 million people infected with HCV with nearly 4 million infected individuals in the United States.
>> Learn more
The HCV NS5B polymerase is essential for viral replication. Virobay is developing NS5B polymerase inhibitors as HCV therapeutics. Virobay compounds are non-nucleoside inhibitors that bind at allosteric sites on the enzyme. Lead compounds exhibit potent antiviral activity in cellular models.
Virobay’s polymerase program is in lead optimization.
